On May 21, 2026 Novartis reported it will present data from more than 65 company or investigator sponsored abstracts at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and the European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited about sharing our latest advancements in radioligand therapy with new Pluvicto data and early insights from our actinium-based RLT," said Mark Rutstein, MD, Global Head, Oncology Development, Novartis. "With a legacy of bold science, our Kisqali and Scemblix data offer continued evidence of how we meaningfully move cancer treatment forward for patients."

Key ASCO (Free ASCO Whitepaper) data highlights include:

Abstract Title Abstract Number/
Presentation Details
Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Subgroup Analyses by Disease Volume and De Novo/Recurrent mHSPC in the PSMAddition Study of [177Lu]Lu-PSMA-617

225Ac-PSMA-617
AcTION: Phase 1 Study of [225Ac]Ac-PSMA-617 (225Ac-PSMA-617) in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC) With or Without Prior [177Lu]Lu-PSMA (177Lu-PSMA) Radioligand Therapy (RLT) Abstract # 5020
Rapid Oral
May 31, 4:30pm – 6:00pm CDT

Abstract # 5010
Oral
June 1, 3:00pm – 4:30pm CDT

Scemblix (asciminib)

ASC4FIRST wk 144 Analysis: Efficacy and Safety and Tolerability With Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS TKIs) in Newly Diagnosed (ND) chronic myeloid leukemia in Chronic Phase (CML-CP)

Abstract #6583
Poster
June 1, 9:00am – 12:00pm CDT
Kisqali (ribociclib)

Prognostic and Predictive Impact of Baseline Gene Expression (Exp) in the NATALEE Trial of Adjuvant (Adj) Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) in HR+/HER2− Early Breast Cancer (EBC)

Abstract #501
Oral
May 30, 1:15pm – 4:15pm CDT
Real-World (RW) Post-Progression Outcomes Following First-Line (1L) Ribociclib (RIB) + Aromatase Inhibitor (AI) Versus AI Alone in African American and Low Socio-Economic Status (SES) Patients (Pts) With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (MBC) in the US

Abstract #1073
Poster
June 1, 1:30pm – 4:30pm CDT

Real-World (RW) Post-Progression Outcomes After First-Line (1L) Treatment With Ribociclib + an Aromatase Inhibitor (AI) vs AI Alone in US Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (MBC) Abstract # e13044
Online publication

Key EHA (Free EHA Whitepaper) data highlights include: 

Abstract Title Abstract Number/ Presentation Details
Scemblix (asciminib)

ASC4FIRST wk 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Abstract # S160
Oral
June 11, 4:45pm – 6:00pm CEST
Ianalumab (VAY736)
Effect of Ianalumab Plus Eltrombopag on Patient-Reported Outcomes in Primary Immune Thrombocytopenia: Results From the VAYHIT2 Phase 3 Trial

Abstract # PF1340
Poster
June 12, 6:45pm – 7:45pm CEST
Pelabresib (DAK539)
Pelabresib Monotherapy in Myelofibrosis After Janus Kinase Inhibitor Failure: Results From Arm 1 of the Open-Label, Phase 2 MANIFEST Study

Abstract # PS1987
Poster
June 13, 6:45pm – 7:45pm CEST
Rapcabtagene autoleucel (YTB323)
Safety, Cellular Kinetics and Early Efficacy of Rapcabtagene Autoleucel (YTB323), a Rapidly Manufactured Autologous CD19 CAR-T Therapy, in Severe, Refractory Autoimmune Diseases

Abstract # PF1241
Poster
June 12, 6:45pm – 7:45pm CEST
Fabhalta (iptacopan)
Iptacopan demonstrates sustained efficacy and safety in paroxysmal nocturnal hemoglobinuria: up to 4 years of follow-up in patients from APPLY, APPOINT and roll-over extension program

Abstract #PS1788
Poster
June 13, 6:45pm – 7:45pm
CEST

Long-term hematologic control and safety in patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan: 6-year follow-up from phase 2 studies and roll-over extension program Abstract # PS1797
Poster
June 13, 6:45pm – 7:45pm
CEST

(Press release, Novartis, MAY 21, 2026, View Source [SID1234665899])

On May 20, 2026 Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses reported that it has closed its previously announced brokered private placement offering ("Brokered Offering") of 19,166,667 units ("Units") of the Company at a price of C$0.24 per Unit ("Offering Price") for gross proceeds of C$4,600,000; including, the full exercise of the over-allotment option. The Brokered Offering was led by Research Capital Corporation as sole agent and sole bookrunner ("Agent").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, the Company is pleased to announce it has closed a concurrent non-brokered private placement offering pursuant to which the Company issued 673,624 Units at the Offering Price for gross proceeds of C$161,669 ("Non-Brokered Offering", together with the Brokered Offering, the "Offering").

In aggregate, the Company raised gross proceeds of C$4,761,669 under the Offering.

Each Unit consists of one common share of the Company ("Common Share") and one common share purchase warrant ("Warrant"). Each Warrant entitles the holder thereof to purchase one Common Share ("Warrant Share") at an exercise price of C$0.32 per Warrant Share at any time until May 20, 2031. The Company has applied to the TSX Venture Exchange ("TSXV") for the listing of the Warrants and the Warrant Shares pursuant to the Brokered Offering. Listing of the Warrants is subject to the approval of the TSXV and there can be no assurance that such approval will be obtained or that the Warrants will be listed.

The Company plans to use the proceeds of the financing to further the Phase II Bacillus Calmette-Guérin ("BCG")-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") clinical study ("Study II") currently underway, commencement of Good Laboratory Practice ("GLP") toxicology analysis for Rutherrin, working capital and general corporate purposes.

The Brokered Offering was completed pursuant to the listed issuer financing exemption and the Non-Brokered Offering was completed by way of private placement pursuant to applicable exemptions from the prospectus requirements, under applicable Canadian securities laws. All securities issued under the Brokered Offering will become free trading on closing and the securities issued under the Non-Brokered Offering are subject to a hold period under applicable Canadian securities laws, which will expire on September 21, 2026. The Offering is subject to final acceptance of the TSX Venture Exchange.

In consideration for their services, the Agent received an aggregate cash commission of C$295,772. The Company also issued 1,232,383 non-transferable compensation options to the Agent ("Compensation Options"), with each Compensation Option exercisable to acquire one Unit at an exercise price of C$0.24 per Unit until May 20, 2031.

Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President, Chief Executive Officer and Chairman of the Board of Theralase, stated that "The Company has successfully raised approximately C$7,500,000 is equity and C$1,000,000 under a recurring line of credit over the last 5 months, in order to strengthen our balance sheet and provide the Company with additional capital to fund our strategic initiatives. In 2026, the Company plans to complete follow-up assessments on the remaining patients in Study II, in order to file new drug applications to both Health Canada and the FDA, under rolling review, seeking Canadian and US marketing approval of its light-activated drug, Ruvidar for bladder cancer. In addition, the Company plans to commence GLP toxicology studies on Rutherrin to allow clinical development, subject to regulatory approval, for a number of cancer indications; including, brain cancer, lung cancer, pancreatic cancer, colorectal cancer and muscle invasive bladder cancer."

Finder’s Fee
In connection with the Non-Brokered Offering, the Company paid a finder’s fee of C$3,000 (payable through the issuance of 12,500 Common Shares) and 6,250 Warrants.

Related Party Transactions
An aggregate of 155,289 Units, representing gross proceeds of C$37,269 were issued to certain insiders of the Corporation. Pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101") and TSX Venture Exchange Policy 5.9, such insider subscriptions are a "related party transaction." The Corporation is exempt from the formal valuation requirement of MI 61-101 in connection with the insider subscriptions in reliance on section 5.5(b) of MI 61-101, as no securities of the Corporation are listed or quoted for trading on the Toronto Stock Exchange, the New York Stock Exchange, the American Stock Exchange, the NASDAQ stock market or any other stock exchange outside of Canada or the United States. Additionally, the Corporation is exempt from obtaining minority shareholder approval in connection with the insider subscriptions in reliance on section 5.7(1)(a) of MI 61-101 as the aggregate value of the insider subscriptions does not exceed 25% of the market capitalization of the Corporation. Due to the limited time between the launch and the close of the Offering, there will be less than 21 days between the date the Corporation files its material change report in respect of the Offering and the completion date of the Offering.

The securities referred to in this news release have not been, and will not be, registered under the United States Securities Act of 1933, as amended ("U.S. Securities Act"), or any applicable securities laws of any state of the United States, and may not be offered or sold within the United States or to, or for, the account or benefit of, U.S. persons (as such term is defined in Regulation S under the U.S. Securities Act) or persons in the United States. unless registered under the U.S. Securities Act and any other applicable securities laws of the United States or an exemption from such registration requirement is available. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the securities offered in any jurisdiction in which such offer, solicitation or sale would be unlawful; including, the United States.

(Press release, Theralase, MAY 20, 2026, View Source [SID1234666033])

On May 20, 2026 Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, reported the release of a Virtual Investor KOL Connect segment featuring Dr. Elena Ratner, Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine and a member of Ernexa’s Board of Directors.
 
As part of the segment, Dr. Ratner discusses ovarian cancer, one of the most difficult malignancies to treat, and highlights the significant challenges patients continue to face throughout diagnosis and treatment. The discussion explores limitations of current therapeutic approaches and the persistent unmet need for more effective and durable treatment options.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Ratner also discusses the evolving ovarian cancer treatment landscape and shares her perspective on Ernexa’s differentiated biological approach to addressing immunologically "cold" tumors. The segment highlights Ernexa’s lead product candidate, ERNA-101, and recently announced preclinical data demonstrating complete tumor elimination and 100% long-term survival in ovarian cancer models when combined with PD-1 blockade.

The discussion also highlights the potential advantages of Ernexa’s engineered allogeneic induced mesenchymal stem cell (iMSC) platform, including the opportunity to develop scalable, off-the-shelf cell therapies designed to improve accessibility and overcome manufacturing challenges associated with traditional autologous approaches.

The Virtual Investor KOL Connect segment featuring Ernexa Therapeutics is now available here. For more information about ERNA-101 and the Company’s development plans, visit www.ernexatx.com

(Press release, Ernexa Therapeutics, MAY 20, 2026, View Source [SID1234665911])

On May 20, 2026 Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on developing Multispecific antibodies in oncology, reported a new development candidate, ISB 2301, a first-in-class, multispecific immune cells (T and NK) activator, for the potential treatment of multiple solid tumor indications. ISB 2301 targets three tumor-associated antigens to trigger tumor cell death and engages both T cells and NK cells to ignite the immune system.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We engineered ISB 2301 to match the biological complexity of solid tumors in a way that conventional immunotherapies have not been able to address," said Lida Pacaud, M.D., President and Chief Executive Officer (CEO). "By simultaneously targeting three tumor-associated antigens and engaging both T cells and NK cells, it deploys a level of multi-mechanistic precision that we believe sets a new benchmark for what multispecific antibodies can achieve in solid tumors."

IGI designed ISB 2301 to induce potent antibody-dependent cellular cytotoxicity (ADCC), potent checkpoint inhibition, and a sustained type 1 immune response. IGI’s proprietary BEAT technology enabled the development of this next-generation multispecific antibody, which can be manufactured with a standard multispecific antibody process. ISB 2301 demonstrates excellent pharmacokinetics, tolerability, and a favorable safety profile in non-human primates. IGI intends to file an IND submission by the end of this year and begin clinical studies in 2027.

"The early-stage clinical success of our prior lead investigational asset, ISB 2001, was a defining moment for IGI in that it attracted a collaboration with AbbVie, validating not just the science, but the platform behind it," Pacaud added. "It’s this same platform that provided the engineering capability to develop such a highly complex molecule as ISB 2301. We look forward to advancing ISB 2301 into clinical studies and exploring the potential of this novel therapeutic approach for cancer patients with solid tumors."

(Press release, Ichnos Glenmark Innovation, MAY 20, 2026, View Source [SID1234665910])

On May 20, 2026 Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, reported that management will participate in the following investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen 7th Annual Oncology Innovation Summit (virtual) – fireside chat, May 27, 2026, at 12:00 p.m. ET
Jefferies Global Healthcare Conference in New York – fireside chat, June 4, 2026, at 11:40 a.m. ET

Webcasts of the fireside chats will be accessible via the "Events & Presentations" section of Monte Rosa’s website at ir.monterosatx.com, and archived versions will be made available for 30 days following the presentations.

(Press release, Monte Rosa Therapeutics, MAY 20, 2026, View Source [SID1234665909])